エピソード
-
"We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity.
Tune in today!
-
"I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon Therapeutics
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financing in the biotech world.
Tune in today!
-
エピソードを見逃しましたか？
-
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they discuss technological innovations in guiding individualized patient treatments.
Tune in today!
-
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." - Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discuss improving and extending the life of every person with cancer and learning from those experiences.
Tune in today!
-
"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge.
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Professor Justin Stebbing, as they discuss insights into oncology, knowledge sharing, and the virtuous circle of translational research.
Tune in today!
-
"Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Mass. General Hospital.
Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, as they discuss insights into new therapeutic interventions for oncology patients.
Tune in today!
-
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to really accelerate medicine's development." - Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School.
Welcome to the February episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Ole Isacson, Professor of Neurology and Neuroscience at Harvard Medical School and Biorasi Scientific Advisory Board member, as they review the integration of AI into the world of neuroscience.
Tune in today!
-
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will Greene, Prader-Willi syndrome patient advocate and Healthcare Engagement Lead at Roche
Welcome to Biorasi's first Few & Far Between episode of 2024! Join host Chris O'Brien and guest Will Greene, Prader-Willi syndrome (PWS) patient advocate and Healthcare Engagement Lead at Roche, as they explore rare disease diagnoses and the importance of newborn screening as a public health tool.
Tune in today!
-
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware of the benefits. And we need to engage the public in defining what those [AI] policies are." Isaac [Zak] Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School
Buckle up for the latest Few & Far Between podcast! We're taking a tour of the current state of AI in healthcare and clinical research. Join host Chris O'Brien and guest Zak Kohane, Professor and Chair, Department of Biomedical Informatics, Harvard Medical School, as they spotlight the evolution of LLMs in the lives of physicians and patients.
-
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh, there's a lot of recreation of the wheel when advocacy groups have not necessarily ever run a research study. And so I kept thinking about what opportunities do we have across rare disease to really elevate and accelerate all of this work around data collection." - Charlene Son Rigby, CEO at Global Genes
Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Charlene Son Rigby, CEO at Global Genes, as they discuss how to build an infrastructure for a world where clinical data is ready to be shared with all those who need it.
-
"So we built the seatbelts before the car, so to speak, wherein we did a project to figure out ways to biocontain these organisms. And the strategy that we used actually drew from all of my past experience in computational protein design and combined it with these incredible new organisms." - Dan Mandell, CEO at GRO Biosciences
Welcome to Biorasi's Few & Far Between podcast! Join host Chris O'Brien and guest Dan Mandell, CEO at GRO Biosciences, as they discuss the latest breakthroughs in protein design - from biocontainment to creating a new amino acid alphabet.
-
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax
Biorasi is excited to welcome Stephanie Wisner to the Few & Far Between podcast. Stephanie is the author of "Building Backwards to Biotech: The Power of Entrepreneurship to Drive Cutting-Edge Science to Market." Join host Chris O'Brien as we explore the multitude of opportunities and pitfalls in today's biotech industry.
Stephanie's book is availabe on Amazaon at https://a.co/d/4afgMpR
-
"What can I contribute that my doctor can't contribute? And that's a real 'a-ha' moment when we share with them how they're the experts in their condition and they know more about the everyday kind of what they go through than their doctor even would because they're not with them 24/7." - Pam Cusick, SVP, Rare Patient Voice
Biorasi's Marc Gas welcomes Pam Cusick, SVP at Rare Patient Voice, to the Few & Far Between podcast for an episode focusing on the power of rare patient input across the clinical trials industry.
Connect with Rare Patient Voice on the road in 2023 at:
UXPA International - Austin, TX - June 20-22
DIA - Boston, MA - June 26-28
Global Genes - San Diego, CA - September 19-21 -
"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that indicate that there may be hope for that patient, we should do something to hear the voice of that patient and learn." - Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH
Welcome back to part two of our conversation with Dr. Francisco Harrison. Join us in this Few & Far Between episode as we dive deeper to discuss new opportunities, new responsibilities, and new experiences...including walking the 500-mile Camino trail from France to the Santiago de Compostela in Spain.
-
"I love clinical research. I will spend my life in clinical research." Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH
Biorasi welcomes Dr. Francisco Harrison to the Few and Far Between podcast for a special two-part episode. In part one, we track Dr. Harrison's origin story - from medical school to his first forays into clinical research.
-
"We work with hundreds of patients a month, helping them understand their own medical history and then tracking what happens to them in the future and providing them and their physicians with decision support and alternative thinking about ways to treat their cancer." Mika Newton, CEO at xCures
Biorasi welcomes Mika Newton to the Few & Far Between podcast to examine how the connection between AI and oncology leads to a more patient-centric world.
-
“I think one of the key insights and observations you make when you have a child who's sick and you spend time with other families who have sick kids is that we all have a tremendous amount of hope that a potential treatment will come to the forefront for our child.” – Dr. Alok Tayi, Founder and CEO of Vibe Bio
Biorasi welcomes Dr. Alok Tayi to the Few & Far Between podcast to explore the power and determination that patients have when it comes to finding a treatment for rare disease.
-
"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific
Welcome back to Part 2 of our special Few & Far Between podcast episode with guest, Jamie Heywood. Continuing our discussion on the role of engineering in clinical research - and making the world a better place for people - we'll explore the path to innovation, including data tracking strategies and securing project funding.
-
"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of engineering." - Jamie Heywood, CEO at Alden Scientific
Biorasi welcomes Jamie Heywood to the Few & Far Between podcast to discuss the critical role engineering plays in clinical research.
- もっと表示する
